JP2024539139A5 - - Google Patents

Info

Publication number
JP2024539139A5
JP2024539139A5 JP2024523624A JP2024523624A JP2024539139A5 JP 2024539139 A5 JP2024539139 A5 JP 2024539139A5 JP 2024523624 A JP2024523624 A JP 2024523624A JP 2024523624 A JP2024523624 A JP 2024523624A JP 2024539139 A5 JP2024539139 A5 JP 2024539139A5
Authority
JP
Japan
Application number
JP2024523624A
Other languages
Japanese (ja)
Other versions
JP2024539139A (ja
JPWO2023070056A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/078465 external-priority patent/WO2023070056A2/en
Publication of JP2024539139A publication Critical patent/JP2024539139A/ja
Publication of JP2024539139A5 publication Critical patent/JP2024539139A5/ja
Publication of JPWO2023070056A5 publication Critical patent/JPWO2023070056A5/ja
Pending legal-status Critical Current

Links

JP2024523624A 2021-10-20 2022-10-20 ヘテロ二量体fcサイトカインおよびその使用 Pending JP2024539139A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163257913P 2021-10-20 2021-10-20
US63/257,913 2021-10-20
PCT/US2022/078465 WO2023070056A2 (en) 2021-10-20 2022-10-20 Heterodimeric fc cytokines and uses thereof

Publications (3)

Publication Number Publication Date
JP2024539139A JP2024539139A (ja) 2024-10-28
JP2024539139A5 true JP2024539139A5 (https=) 2025-10-22
JPWO2023070056A5 JPWO2023070056A5 (https=) 2025-10-22

Family

ID=86059699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523624A Pending JP2024539139A (ja) 2021-10-20 2022-10-20 ヘテロ二量体fcサイトカインおよびその使用

Country Status (11)

Country Link
US (2) US12522639B2 (https=)
EP (1) EP4419545A4 (https=)
JP (1) JP2024539139A (https=)
KR (1) KR20240099287A (https=)
CN (1) CN118451096A (https=)
AU (1) AU2022369312A1 (https=)
CA (1) CA3234552A1 (https=)
IL (1) IL312221A (https=)
MX (1) MX2024004763A (https=)
WO (1) WO2023070056A2 (https=)
ZA (1) ZA202403036B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021231773A1 (en) 2020-05-13 2021-11-18 Good Therapeutics, Inc. Compositions of protein complexes and methods of use thereof
JP2024539139A (ja) 2021-10-20 2024-10-28 シンセカイン インコーポレイテッド ヘテロ二量体fcサイトカインおよびその使用
AU2023309859A1 (en) * 2022-07-18 2025-01-23 Onko-Innate Pty Ltd Il-12 fc fusion proteins and uses thereof
WO2024238212A1 (en) * 2023-05-12 2024-11-21 Chimeris Uk Ltd. Car t-cells secreting specificity detuned cytokine il-12
WO2025012105A2 (en) * 2023-07-07 2025-01-16 Technische Universitaet Muenchen, In Vertretung Des Freistaates Bayern Muteins of human interleukin 12
WO2025136986A2 (en) 2023-12-18 2025-06-26 Genzyme Corporation Il-12 loss of potency muteins

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5573764A (en) 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1489100B1 (en) 1997-12-08 2016-06-15 Merck Patent GmbH Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
JP4793971B2 (ja) 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US7083970B2 (en) 2001-04-19 2006-08-01 The Scripps Research Institute Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs
BRPI0408247A (pt) 2003-03-10 2006-03-01 Schering Corp usos de antagonistas e agonistas de il-23 e reagentes relacionados
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US8802643B1 (en) 2003-05-30 2014-08-12 University Of South Florida Method for the treatment of malignancies
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN103145839A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
BRPI0620648B1 (pt) 2005-12-30 2022-12-20 Merck Patent Gesellschaft Mit Beschrãnkter Haftung Variante de il-12 p40, proteínas il-12, il-23 e de fusão, composição farmacêutica e uso da mesma
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
EP2389192A4 (en) 2009-01-23 2013-01-16 Biogen Idec Inc STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHOD OF USE
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
US9714291B2 (en) 2012-10-05 2017-07-25 Kyowa Hakko Kirin Co., Ltd Heterodimer protein composition
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
PT3107573T (pt) 2014-02-19 2019-01-10 Merck Patent Gmbh Imunoterapia com il-12 visada ao cancro
SG11201702295UA (en) 2014-09-22 2017-04-27 Intrexon Corp Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
US11087249B2 (en) 2016-05-24 2021-08-10 Ciambella Ltd. Method and apparatus for triggering execution of a workflow over a network
MX386014B (es) * 2016-08-10 2025-03-18 Univ Ajou Ind Academic Coop Found Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma.
US10232053B2 (en) 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
SG11201907299XA (en) 2017-02-08 2019-09-27 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SE541511C2 (sv) 2017-03-06 2019-10-22 Slaettberg Fredrik Installationsklara vägg- och regelkassetter
CN110101843A (zh) 2018-02-01 2019-08-09 北京科诺科服生物科技有限公司 一种抗肿瘤蛋白质及其应用
EA202091887A1 (ru) 2018-02-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
CN110396133B (zh) 2018-04-25 2021-07-23 免疫靶向有限公司 一种以白介素12为活性成分的融合蛋白型药物前体
CA3100005A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
EP3861016A2 (en) * 2018-10-03 2021-08-11 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
AU2019366956B2 (en) 2018-10-23 2025-10-30 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins
MX2022000991A (es) 2019-07-25 2022-05-24 Univ Chicago Composiciones y metodos que comprenden agentes terapeuticos activados por proteasa.
CN115916233A (zh) * 2019-10-03 2023-04-04 Xencor股份有限公司 靶向IL-12异源二聚体Fc融合蛋白
EP4090674A4 (en) 2020-01-14 2024-01-24 Synthekine, Inc. Biased il2 muteins methods and compositions
CN121319219A (zh) 2020-01-14 2026-01-13 辛德凯因股份有限公司 Il2突变蛋白
IL297186A (en) 2020-04-17 2022-12-01 Univ Leland Stanford Junior Transgenic il-12 and il-23 polypeptides and their uses
US20230272041A1 (en) 2020-04-22 2023-08-31 Dragonfly Therapeutics, Inc. Formulation, Dosage Regimen, and Manufacturing Process for Heterodimeric FC-Fused Proteins
CA3217079A1 (en) 2021-05-05 2022-11-10 Michael Schmidt Fusion polypeptides
JP2024540938A (ja) * 2021-10-20 2024-11-06 シンセカイン インコーポレイテッド ヒトIL-12p40バリアントおよびその使用
JP2024539139A (ja) 2021-10-20 2024-10-28 シンセカイン インコーポレイテッド ヘテロ二量体fcサイトカインおよびその使用

Similar Documents

Publication Publication Date Title
JP2024528665A5 (https=)
JP2024534468A5 (https=)
BR102022025291A2 (https=)
CL2025003666A1 (es) Fertilizantes granulares recubiertos con métricas de calidad mejoradas.
CL2025003660A1 (es) Aparato de filtración y método de control del aparato de filtración
CL2025003587A1 (es) Nuevos dispositivos de drenaje y su uso.
CL2025003270A1 (es) Composición antiparasitaria controlar infecciones parasitarias en colmenas
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
CN307046923S (https=)
CN307045991S (https=)
CN307046032S (https=)
BY23969C1 (https=)
BY23968C1 (https=)
BY23967C1 (https=)
CN307046285S (https=)
BY23963C1 (https=)
BY13176U (https=)
BY13144U (https=)
BY13175U (https=)